Aubagne, April 14, 2015 - Sartorius Stedim Biotech, a leading supplier for the biopharmaceutical industry, today pre-announced results for the first quarter 2015. Based on preliminary figures sales revenue grew around 22% in constant currencies to approximately €204 million (reported gain: around 33%).

Due to the low prior-year revenue base, the company had expected above-average growth rates for this first quarter. Nevertheless, the gains supported by strong performance in all product segments were higher than projected at the beginning of the year.

Based on the results of the first three months, Sartorius Stedim Biotech has revised its forecast upwards for the full year of 2015. Sales revenue in constant currencies is now expected to increase approximately 7% to 10% (previous guidance: approx. 4% to 7%). Management projects that the company's underlying EBITDA margin in constant currencies will reach around 24.5% to 25% (previous guidance: around 24.0% to 24.5%).

Further information will be published on April 20, 2015.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

distributed by